The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-01-09

AUTHORS

Michael Nurmohamed, Ernest Choy, Sadiq Lula, Blerina Kola, Ryan DeMasi, Paola Accossato

ABSTRACT

INTRODUCTION: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent years, treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), either as monotherapy or in combination with other drugs, have become the standard of treatment. In this systematic literature review, we evaluated the effect of treatment with biologic or tofacitinib on the CV risk and outcomes in these patients. METHODS: A systematic search was performed in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for articles reporting on CV risk and events in patients with rheumatic disease treated with a biologic agent or tofacitinib. Articles identified were subjected to two levels of screening. Articles that passed the first level based on title and abstract were assessed on full-text evaluation. The quality of randomized clinical trials was assessed by Jadad scoring system and the quality of the other studies and abstracts was assessed using the Downs and Black instrument. The data extracted included study design, baseline patient characteristics, and measurements of CV risk and events. RESULTS: Of the 5722 articles identified in the initial search, screening yielded 105 unique publications from 90 unique studies (33 clinical trials, 39 prospective cohort studies, and an additional 18 retrospective studies) that reported CV risk outcomes. A risk of bias analysis for each type of report indicated that they were of good or excellent quality. Importantly, despite some limitations in data reported, there were no indications of significant increase in adverse CV events or risk in response to treatment with the agents evaluated. CONCLUSIONS: Treatment with biologic or tofacitinib appears to be well-tolerated with respect to CV outcomes in these patients. More... »

PAGES

473-488

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40264-017-0628-9

DOI

http://dx.doi.org/10.1007/s40264-017-0628-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100269781

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29318514


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Products", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rheumatic Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Reade, VU University Medical Center, 3A50, Amsterdam Rheumatology and Immunology Center, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Rheumatology, Reade, VU University Medical Center, 3A50, Amsterdam Rheumatology and Immunology Center, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nurmohamed", 
        "givenName": "Michael", 
        "id": "sg:person.012737666714.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012737666714.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiff University School of Medicine, Cardiff, Wales UK", 
          "id": "http://www.grid.ac/institutes/grid.5600.3", 
          "name": [
            "Cardiff University School of Medicine, Cardiff, Wales UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choy", 
        "givenName": "Ernest", 
        "id": "sg:person.01345733561.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345733561.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Present Address: IQVIA, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Envision Pharma Group, London, UK", 
            "Present Address: IQVIA, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lula", 
        "givenName": "Sadiq", 
        "id": "sg:person.0701424133.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701424133.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Tadworth, Surrey UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer, Tadworth, Surrey UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kola", 
        "givenName": "Blerina", 
        "id": "sg:person.0641601504.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641601504.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Collegeville, PA USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, Collegeville, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "DeMasi", 
        "givenName": "Ryan", 
        "id": "sg:person.010603656605.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010603656605.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.439132.e", 
          "name": [
            "Pfizer, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Accossato", 
        "givenName": "Paola", 
        "id": "sg:person.015354675124.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015354675124.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-013-2369-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027014218", 
          "https://doi.org/10.1007/s10067-013-2369-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-010-1388-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003317313", 
          "https://doi.org/10.1007/s10067-010-1388-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-014-2841-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003960577", 
          "https://doi.org/10.1007/s10067-014-2841-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00393-011-0899-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027018097", 
          "https://doi.org/10.1007/s00393-011-0899-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar3058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044003622", 
          "https://doi.org/10.1186/ar3058"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-014-0459-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012551410", 
          "https://doi.org/10.1007/s11926-014-0459-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrrheum.2015.112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006107871", 
          "https://doi.org/10.1038/nrrheum.2015.112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1546-0096-11-s2-p178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021154790", 
          "https://doi.org/10.1186/1546-0096-11-s2-p178"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-01-09", 
    "datePublishedReg": "2018-01-09", 
    "description": "INTRODUCTION: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent years, treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), either as monotherapy or in combination with other drugs, have become the standard of treatment. In this systematic literature review, we evaluated the effect of treatment with biologic or tofacitinib on the CV risk and outcomes in these patients.\nMETHODS: A systematic search was performed in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for articles reporting on CV risk and events in patients with rheumatic disease treated with a biologic agent or tofacitinib. Articles identified were subjected to two levels of screening. Articles that passed the first level based on title and abstract were assessed on full-text evaluation. The quality of randomized clinical trials was assessed by Jadad scoring system and the quality of the other studies and abstracts was assessed using the Downs and Black instrument. The data extracted included study design, baseline patient characteristics, and measurements of CV risk and events.\nRESULTS: Of the 5722 articles identified in the initial search, screening yielded 105 unique publications from 90 unique studies (33 clinical trials, 39 prospective cohort studies, and an additional 18 retrospective studies) that reported CV risk outcomes. A risk of bias analysis for each type of report indicated that they were of good or excellent quality. Importantly, despite some limitations in data reported, there were no indications of significant increase in adverse CV events or risk in response to treatment with the agents evaluated.\nCONCLUSIONS: Treatment with biologic or tofacitinib appears to be well-tolerated with respect to CV outcomes in these patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40264-017-0628-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096281", 
        "issn": [
          "0114-5916", 
          "1179-1942"
        ], 
        "name": "Drug Safety", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "41"
      }
    ], 
    "keywords": [
      "disease-modifying anti-rheumatic drugs", 
      "CV risk", 
      "rheumatic diseases", 
      "synthetic disease-modifying anti-rheumatic drugs", 
      "Jadad scoring system", 
      "anti-rheumatic drugs", 
      "Cochrane Central Register", 
      "baseline patient characteristics", 
      "adverse CV events", 
      "cardiovascular risk factors", 
      "impact of biologics", 
      "randomized clinical trials", 
      "standard of treatment", 
      "full-text evaluation", 
      "effect of treatment", 
      "systematic literature review", 
      "CV events", 
      "CV outcomes", 
      "Central Register", 
      "patient characteristics", 
      "Controlled Trials", 
      "biologic agents", 
      "Cochrane Database", 
      "risk factors", 
      "inflammatory diseases", 
      "clinical trials", 
      "cardiovascular disease", 
      "patients", 
      "Black instrument", 
      "systematic review", 
      "scoring system", 
      "literature review", 
      "study design", 
      "disease", 
      "major cause", 
      "initial search", 
      "systematic search", 
      "biologics", 
      "unique publications", 
      "outcomes", 
      "tofacitinib", 
      "treatment", 
      "significant increase", 
      "risk", 
      "risk outcomes", 
      "unique studies", 
      "trials", 
      "drugs", 
      "bias analysis", 
      "review", 
      "monotherapy", 
      "EMBASE", 
      "MEDLINE", 
      "agents", 
      "mortality", 
      "levels", 
      "events", 
      "study", 
      "cause", 
      "Register", 
      "types of reports", 
      "indications", 
      "report", 
      "years", 
      "quality", 
      "search", 
      "response", 
      "excellent quality", 
      "data", 
      "factors", 
      "evaluation", 
      "database", 
      "increase", 
      "effect", 
      "recent years", 
      "combination", 
      "article", 
      "publications", 
      "types", 
      "standards", 
      "impact", 
      "analysis", 
      "instrument", 
      "limitations", 
      "characteristics", 
      "title", 
      "Abstract", 
      "measurements", 
      "respect", 
      "down", 
      "first level", 
      "system", 
      "design", 
      "CV risk outcomes"
    ], 
    "name": "The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review", 
    "pagination": "473-488", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100269781"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40264-017-0628-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29318514"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40264-017-0628-9", 
      "https://app.dimensions.ai/details/publication/pub.1100269781"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_766.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40264-017-0628-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40264-017-0628-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40264-017-0628-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40264-017-0628-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40264-017-0628-9'


 

This table displays all metadata directly associated to this object as RDF triples.

291 TRIPLES      22 PREDICATES      140 URIs      124 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40264-017-0628-9 schema:about N0d93d70b0a4542c0863d35a216b0f0f3
2 N140fc5d4cba84c338a28d90436ed120d
3 N18f6f9ba61924c34a766f977413d82f3
4 N1ebce499eb2843f690c86a85f9de5b52
5 N2da5ac51f0d1409b9d1c5b15cdab6b34
6 N3c1073900bac405091a0c108cb5bd585
7 N44fb2ff407a14d538f19f6f3aaf257c5
8 N48b632852ef7409492fc15194055030f
9 N57e31313f38343669fe79fb11eba8773
10 N5c4c29ae0afd4af39662139bb8ea11d3
11 N85aded2ec2894d54be5274e3f6429dcb
12 N90d6d9227f614913a483d4c1f52315b7
13 Nb592ccfa1315449abf13df0d71f3282a
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N4989f4e0e0ff401fa1e7f7a8752d6185
17 schema:citation sg:pub.10.1007/s00393-011-0899-y
18 sg:pub.10.1007/s10067-010-1388-4
19 sg:pub.10.1007/s10067-013-2369-1
20 sg:pub.10.1007/s10067-014-2841-6
21 sg:pub.10.1007/s11926-014-0459-y
22 sg:pub.10.1038/nrrheum.2015.112
23 sg:pub.10.1186/1546-0096-11-s2-p178
24 sg:pub.10.1186/ar3058
25 schema:datePublished 2018-01-09
26 schema:datePublishedReg 2018-01-09
27 schema:description INTRODUCTION: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent years, treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), either as monotherapy or in combination with other drugs, have become the standard of treatment. In this systematic literature review, we evaluated the effect of treatment with biologic or tofacitinib on the CV risk and outcomes in these patients. METHODS: A systematic search was performed in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for articles reporting on CV risk and events in patients with rheumatic disease treated with a biologic agent or tofacitinib. Articles identified were subjected to two levels of screening. Articles that passed the first level based on title and abstract were assessed on full-text evaluation. The quality of randomized clinical trials was assessed by Jadad scoring system and the quality of the other studies and abstracts was assessed using the Downs and Black instrument. The data extracted included study design, baseline patient characteristics, and measurements of CV risk and events. RESULTS: Of the 5722 articles identified in the initial search, screening yielded 105 unique publications from 90 unique studies (33 clinical trials, 39 prospective cohort studies, and an additional 18 retrospective studies) that reported CV risk outcomes. A risk of bias analysis for each type of report indicated that they were of good or excellent quality. Importantly, despite some limitations in data reported, there were no indications of significant increase in adverse CV events or risk in response to treatment with the agents evaluated. CONCLUSIONS: Treatment with biologic or tofacitinib appears to be well-tolerated with respect to CV outcomes in these patients.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N5d056f75d235405899db1465b8d57c59
32 N8c04715985594ffeb9ab9132704e5cff
33 sg:journal.1096281
34 schema:keywords Abstract
35 Black instrument
36 CV events
37 CV outcomes
38 CV risk
39 CV risk outcomes
40 Central Register
41 Cochrane Central Register
42 Cochrane Database
43 Controlled Trials
44 EMBASE
45 Jadad scoring system
46 MEDLINE
47 Register
48 adverse CV events
49 agents
50 analysis
51 anti-rheumatic drugs
52 article
53 baseline patient characteristics
54 bias analysis
55 biologic agents
56 biologics
57 cardiovascular disease
58 cardiovascular risk factors
59 cause
60 characteristics
61 clinical trials
62 combination
63 data
64 database
65 design
66 disease
67 disease-modifying anti-rheumatic drugs
68 down
69 drugs
70 effect
71 effect of treatment
72 evaluation
73 events
74 excellent quality
75 factors
76 first level
77 full-text evaluation
78 impact
79 impact of biologics
80 increase
81 indications
82 inflammatory diseases
83 initial search
84 instrument
85 levels
86 limitations
87 literature review
88 major cause
89 measurements
90 monotherapy
91 mortality
92 outcomes
93 patient characteristics
94 patients
95 publications
96 quality
97 randomized clinical trials
98 recent years
99 report
100 respect
101 response
102 review
103 rheumatic diseases
104 risk
105 risk factors
106 risk outcomes
107 scoring system
108 search
109 significant increase
110 standard of treatment
111 standards
112 study
113 study design
114 synthetic disease-modifying anti-rheumatic drugs
115 system
116 systematic literature review
117 systematic review
118 systematic search
119 title
120 tofacitinib
121 treatment
122 trials
123 types
124 types of reports
125 unique publications
126 unique studies
127 years
128 schema:name The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
129 schema:pagination 473-488
130 schema:productId N17fe0b97b35348a6bbec0c6a74c40e6d
131 N5a7a357d38fd48eea9a0f66c1dba7a14
132 N8a8f0733ae654f56bac94723aaede65c
133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100269781
134 https://doi.org/10.1007/s40264-017-0628-9
135 schema:sdDatePublished 2021-11-01T18:33
136 schema:sdLicense https://scigraph.springernature.com/explorer/license/
137 schema:sdPublisher Nd98d5b01805948e0bc634a4200b4c860
138 schema:url https://doi.org/10.1007/s40264-017-0628-9
139 sgo:license sg:explorer/license/
140 sgo:sdDataset articles
141 rdf:type schema:ScholarlyArticle
142 N0d93d70b0a4542c0863d35a216b0f0f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Biological Products
144 rdf:type schema:DefinedTerm
145 N10ed13bf659a4d6b965f1de1cdf0e787 rdf:first sg:person.015354675124.15
146 rdf:rest rdf:nil
147 N140fc5d4cba84c338a28d90436ed120d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Prospective Studies
149 rdf:type schema:DefinedTerm
150 N17fe0b97b35348a6bbec0c6a74c40e6d schema:name pubmed_id
151 schema:value 29318514
152 rdf:type schema:PropertyValue
153 N18f6f9ba61924c34a766f977413d82f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Clinical Trials as Topic
155 rdf:type schema:DefinedTerm
156 N1ebce499eb2843f690c86a85f9de5b52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Rheumatic Diseases
158 rdf:type schema:DefinedTerm
159 N2da5ac51f0d1409b9d1c5b15cdab6b34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Retrospective Studies
161 rdf:type schema:DefinedTerm
162 N3c1073900bac405091a0c108cb5bd585 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Pyrroles
164 rdf:type schema:DefinedTerm
165 N3c2a140170ef4cd3a0f29219506d2882 rdf:first sg:person.0641601504.09
166 rdf:rest N9a1288997d7e4e81a191f27cdec3b3b7
167 N44fb2ff407a14d538f19f6f3aaf257c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Pyrimidines
169 rdf:type schema:DefinedTerm
170 N48b632852ef7409492fc15194055030f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cardiovascular Diseases
172 rdf:type schema:DefinedTerm
173 N4989f4e0e0ff401fa1e7f7a8752d6185 rdf:first sg:person.012737666714.04
174 rdf:rest N4d4f1939e8674612b4f9cfe63929e6ce
175 N4d4f1939e8674612b4f9cfe63929e6ce rdf:first sg:person.01345733561.44
176 rdf:rest Nea9d449befcc4fb2ab6967aa22aca985
177 N57e31313f38343669fe79fb11eba8773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Piperidines
179 rdf:type schema:DefinedTerm
180 N5a7a357d38fd48eea9a0f66c1dba7a14 schema:name dimensions_id
181 schema:value pub.1100269781
182 rdf:type schema:PropertyValue
183 N5c4c29ae0afd4af39662139bb8ea11d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Animals
185 rdf:type schema:DefinedTerm
186 N5d056f75d235405899db1465b8d57c59 schema:volumeNumber 41
187 rdf:type schema:PublicationVolume
188 N85aded2ec2894d54be5274e3f6429dcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Antirheumatic Agents
190 rdf:type schema:DefinedTerm
191 N8a8f0733ae654f56bac94723aaede65c schema:name doi
192 schema:value 10.1007/s40264-017-0628-9
193 rdf:type schema:PropertyValue
194 N8c04715985594ffeb9ab9132704e5cff schema:issueNumber 5
195 rdf:type schema:PublicationIssue
196 N90d6d9227f614913a483d4c1f52315b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Humans
198 rdf:type schema:DefinedTerm
199 N9a1288997d7e4e81a191f27cdec3b3b7 rdf:first sg:person.010603656605.52
200 rdf:rest N10ed13bf659a4d6b965f1de1cdf0e787
201 Nb592ccfa1315449abf13df0d71f3282a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Risk Factors
203 rdf:type schema:DefinedTerm
204 Nd98d5b01805948e0bc634a4200b4c860 schema:name Springer Nature - SN SciGraph project
205 rdf:type schema:Organization
206 Nea9d449befcc4fb2ab6967aa22aca985 rdf:first sg:person.0701424133.37
207 rdf:rest N3c2a140170ef4cd3a0f29219506d2882
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
212 schema:name Clinical Sciences
213 rdf:type schema:DefinedTerm
214 sg:journal.1096281 schema:issn 0114-5916
215 1179-1942
216 schema:name Drug Safety
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.010603656605.52 schema:affiliation grid-institutes:grid.410513.2
220 schema:familyName DeMasi
221 schema:givenName Ryan
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010603656605.52
223 rdf:type schema:Person
224 sg:person.012737666714.04 schema:affiliation grid-institutes:grid.16872.3a
225 schema:familyName Nurmohamed
226 schema:givenName Michael
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012737666714.04
228 rdf:type schema:Person
229 sg:person.01345733561.44 schema:affiliation grid-institutes:grid.5600.3
230 schema:familyName Choy
231 schema:givenName Ernest
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345733561.44
233 rdf:type schema:Person
234 sg:person.015354675124.15 schema:affiliation grid-institutes:grid.439132.e
235 schema:familyName Accossato
236 schema:givenName Paola
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015354675124.15
238 rdf:type schema:Person
239 sg:person.0641601504.09 schema:affiliation grid-institutes:grid.418566.8
240 schema:familyName Kola
241 schema:givenName Blerina
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641601504.09
243 rdf:type schema:Person
244 sg:person.0701424133.37 schema:affiliation grid-institutes:None
245 schema:familyName Lula
246 schema:givenName Sadiq
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701424133.37
248 rdf:type schema:Person
249 sg:pub.10.1007/s00393-011-0899-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1027018097
250 https://doi.org/10.1007/s00393-011-0899-y
251 rdf:type schema:CreativeWork
252 sg:pub.10.1007/s10067-010-1388-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003317313
253 https://doi.org/10.1007/s10067-010-1388-4
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/s10067-013-2369-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027014218
256 https://doi.org/10.1007/s10067-013-2369-1
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s10067-014-2841-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003960577
259 https://doi.org/10.1007/s10067-014-2841-6
260 rdf:type schema:CreativeWork
261 sg:pub.10.1007/s11926-014-0459-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1012551410
262 https://doi.org/10.1007/s11926-014-0459-y
263 rdf:type schema:CreativeWork
264 sg:pub.10.1038/nrrheum.2015.112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006107871
265 https://doi.org/10.1038/nrrheum.2015.112
266 rdf:type schema:CreativeWork
267 sg:pub.10.1186/1546-0096-11-s2-p178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021154790
268 https://doi.org/10.1186/1546-0096-11-s2-p178
269 rdf:type schema:CreativeWork
270 sg:pub.10.1186/ar3058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044003622
271 https://doi.org/10.1186/ar3058
272 rdf:type schema:CreativeWork
273 grid-institutes:None schema:alternateName Present Address: IQVIA, London, UK
274 schema:name Envision Pharma Group, London, UK
275 Present Address: IQVIA, London, UK
276 rdf:type schema:Organization
277 grid-institutes:grid.16872.3a schema:alternateName Department of Rheumatology, Reade, VU University Medical Center, 3A50, Amsterdam Rheumatology and Immunology Center, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands
278 schema:name Department of Rheumatology, Reade, VU University Medical Center, 3A50, Amsterdam Rheumatology and Immunology Center, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands
279 rdf:type schema:Organization
280 grid-institutes:grid.410513.2 schema:alternateName Pfizer, Collegeville, PA USA
281 schema:name Pfizer, Collegeville, PA USA
282 rdf:type schema:Organization
283 grid-institutes:grid.418566.8 schema:alternateName Pfizer, Tadworth, Surrey UK
284 schema:name Pfizer, Tadworth, Surrey UK
285 rdf:type schema:Organization
286 grid-institutes:grid.439132.e schema:alternateName Pfizer, Rome, Italy
287 schema:name Pfizer, Rome, Italy
288 rdf:type schema:Organization
289 grid-institutes:grid.5600.3 schema:alternateName Cardiff University School of Medicine, Cardiff, Wales UK
290 schema:name Cardiff University School of Medicine, Cardiff, Wales UK
291 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...